Board approves NCD issuance up to Rs 800 crore on private placement basis

Fund Raising View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.8%Reaction day

₹930.00

prior close

₹914.80

announcement price

In-mkt

timing

Nifty Microcap 250market+0.8%+2.9% vs market

Pharmaceuticals peers, median of 167sector-0.1%+3.9% vs sector

On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.3

15m

-0.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.8+0.8+2.9-0.1+3.9

Next day

+2.2+1.0+1.1-0.1+2.3

+0.5+1.7-1.2-0.3+0.8

+0.4+0.1+0.3-1.0+1.3

+0.5+0.8-0.2-0.8+1.4

+1.3-0.9+2.2-2.3+3.6

-0.4-4.5+4.0-4.7+4.2

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova board approved issuance of secured or unsecured, listed, rated, redeemable Non-Convertible Debentures on a private placement basis. Up to 80,000 NCDs of face value Rs 1,00,000 each, totalling up to Rs 800 crore, to be issued in one or more tranches with tenure up to 5 years. Coupon to be discovered through bidding. Also seeking shareholder approval via postal ballot for NCD borrowings up to Rs 2,500 crore outstanding at any time over the next year.

Likely market impact

Debt raise of up to Rs 800 crore may lift interest costs and leverage, but provides capital for business growth or refinancing needs.